Financials
Financial year 2025
Worth noting
- Figures corrected afterwards (2023).
Revenue
€ 4,622.6 million
▲ 10% vs 2024
Profit
Growing€ 4,239.7 million
▲ 347% vs 2024
Debts
Low€ 4,371.1 million
▲ 11% vs 2024
UCB PHARMA from Anderlecht, company number BE0403096168, closed financial year 2025 with a result of € 4,239.7 million after tax. For that financial year UCB PHARMA recorded revenue of € 4,622.6 million and equity of € 16,234.8 million. Compared with financial year 2024, the result moved from € 947.4 million to € 4,239.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 19, 2026.
What happened at UCB PHARMA?
What happened at UCB PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jean-Christophe TELLIER stepped down as director. NBB
- Kirsten LUND-JÜRGENSEN stepped down as director. NBB
- Caroline VANCOILLIE stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 4,239.7 million (▲ 347% vs 2024). Source: NBB ↗
- Jean-Christophe TELLIER became a director. NBB
- New establishment in Leuven. KBO
- Kirsten LUND-JÜRGENSEN became a director. NBB
- Caroline VANCOILLIE became a director. NBB
In short
From € 612.6 million profit in 2021 to € 4,239.7 million profit in 2025.
Paid € 299 million in corporate taxes since 2021.
Best year ever: 2025, with € 4,239.7 million profit.
Paid out € 1,600 million in dividends to the owners in total.
A new publication or filing at UCB PHARMA? We notify you, reason included.
Follow UCB PHARMANeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by UCB SA (100%) and UCB Fipar SA (0%). It owns 100% of UCB Belgium, 100% of UCB Pharma Oy, 100% of UCB Pharma B.V., 100% of UCB Farchim SA (AG - Ltd), 100% of UCB Pharma A.S. and 100% of UCB Nordic AS itself.
Directors
According to the 2025 annual accounts
Jean-Christophe TELLIER
Chairman of the board
Also active at: UCB Fipar, UCB Ventures, UCB Ventures Belgium
since 2023 · until 2029
Kirsten LUND-JÜRGENSEN
Director
since 2022 · until 2028
since 2022 · until 2028
Shareholders
100%
0%
Participations
100%
UCB Pharma Oy
100%
UCB Pharma B.V.
100%
UCB Farchim SA (AG - Ltd)
100%
UCB Pharma A.S.
100%
UCB Nordic AS
100%
100%
UCB Holdings, Inc.
100%
UCB Pharma Ab
100%
UCB Pharma GmbH Austria
100%
UCB GmbH
94.8%
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Chemin du Foriest /
1420 Braine-l'Alleud
Active since 20 December 2006
Gaston Geenslaan 14
3001 Leuven
Active since 1 March 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
UCB Belgium same network
U C B same network
UCB Fipar same network
Fondation Emmanuel Janssen
UCB BIOPHARMA same network
€ 3,642.1 million revenue · 2025
+5 more
Details
- Company number
- 0403.096.168
- VAT number
- BE 0403.096.168
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 February 1968
- Peppol
- Active · Active since 2 Dec 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten